MESSAGE FROM THE DIRECTOR
Case CCC Annual Scientific Retreat
Dear Cancer Center Members:
The annual scientific retreat of the Cancer Center will be July 8-9 at Corporate College East. For those of you unfamiliar with this facility, it offers a nice, open layout that is conducive to both large and small gatherings, and is only about 10 miles from University Circle.
As we are in full planning mode for our CCSG renewal, there will be emphasis on the Cancer Center's strategic plan, but along with the Director's overview and the individual program meetings, Friday's schedule includes scientific presentations highlighting some great science in Tumor Microenvironment, Cancer Cellular Dynamics, Cancer Prevention and Population Sciences, and Targeted Cancer Therapies.
This year, we have added a concurrent session for students, fellows, and other trainees, which will be an open session offering career guidance in a Q&A format. Panelists will be junior faculty who can offer different perspectives on the postdoctoral and early faculty experiences. There will also be discussion about starting translational research projects. Encourage your trainees to come prepared with questions for the panelists.
As the scientific poster session at last year's retreat was such a success, we will have one again, with awards to the top five posters. Over 65 trainees have submitted abstracts. We have also added a poster session featuring the shared resources of the Cancer Center. Poster discussions will be concurrent with food and drink, as this year's dinner will be casual to encourage as much interaction among members as possible.
Saturday's session has more of a clinical focus, but all members will benefit from the presentations on translational opportunities in cancer center clinical programs, followed by information on the availability of tissue from the national cooperative groups and funding opportunities for early phase trials. Come early to have breakfast and engage with the core directors at the continuation of the core facility poster session that begins Friday afternoon.
Our wrap up session on Saturday, Cross Cutting Opportunities and Resources, will bring some new perspectives to our retreat. The session features presentations on the cutting-edge topics of clinicopathologic databases, home grown drugs, and technology commercialization.
Thank you for your continued commitment to the Cancer Center. I look forward to seeing you on July 8-9.
Stan Gerson, MD
Director, Case Comprehensive Cancer Center
* * * * * * * *
Registration | Agenda | Retreat Homepage
The Cancer Center has a block of rooms for a reduced rate at the Marriott Cleveland East, which is across from Corporate College East. Click here to reserve a room at your own expense of $114 per night.
CASE CCC IN THE NEWS
Key Function of Enzyme Involved in RNA Processing Described
Science Daily (press release) - Jun 9, 2011
In their work, the researchers led by Eckhard Jankowsky, PhD, researcher and associate professor in the Center for RNA Molecular Biology at the Case Western Reserve University School of Medicine, examined the function of TRAMP, a protein complex ...
Prostate Cancer- Non-Invasive Treatment Of Kidney And Prostate Cancer Revealed
Star Global Tribune - Jun 9, 2011
"The development of stereotactic radiosurgery capabilities has opened up new possibilities for the non-invasive treatment of kidney and prostate cancer," said Lee E. Ponsky, MD, director of the Center for Urologic Oncology and Minimally Invasive Therapies at University Hospitals Case Medical Center in Cleveland. "Urologists and surgeons need to be aware of these developments, and work closely with colleagues in radiation oncology to evaluate the role of radiosurgery in the treatment of prostate and kidney cancer."...
University Hospitals Oncologist's Breast Cancer Pilot Study: Whatever Happened To...?
Plain Dealer (blog) - Jun 6, 2011
"We've essentially started [again] from scratch," said oncologist Dr. Joseph Baar, who has been working on creating a vaccine that would use a patient's own immune system to target and kill cancer cells. "The vaccine study is ongoing, ...
Cancer Drug Avastin Makes Inroads Against Ovarian Tumors
U.S. News & World Report - Jun 4, 2011
But the high cost of Avastin (as much as $6000 a month) could be prohibitive, especially given that other therapeutic options are available to women in each group, said Dr. Kristine Zanotti, a gynecologic oncologist with University Hospitals of ...
Pilot Project Grants: American Cancer Society IRG Awards
The Case CCC is currently accepting applications for American Cancer Society Institutional Research Grant (IRG) awards. Pilot funding is available for projects in basic, clinical, prevention and control, behavioral, health services, and epidemiology cancer research with awards up to $30,000 for one-year cancer research projects that provide the basis for future independent grants.
Instructions, frequently asked questions, and application forms are available at http://cancer.case.edu. Contact Terri Daso, Cancer Center Administration (844-7252,email@example.com) for more information.
LOI Deadline: TODAY: June 13
AACR Team Science Award
Application Deadline: July 5, 2011
Nominations are currently being accepted for the AACR Team Science Award. This award has been established by the American Association for Cancer Research and Eli Lilly and Company to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. Proactive interaction between academic and industry researchers is particularly crucial to continue progress and accelerate drug development.
Deadline: September 6
Pezcoller Foundation-AACR International Award for Cancer Research
Nominations are now being accepted for the Pezcoller Foundation-AACR International Award for Cancer Research. The award is intended to honor an individual scientist. However, more than one scientist may be co-nominated and selected to share the award when their investigations are closely related in subject matter and have resulted in work that is worthy of the award.
The purpose of this award is to recognize a scientist of international renown:
- who has made a major scientific discovery in basic cancer research OR who has made significant contributions to translational cancer research;
- who continues to be active in cancer research and has a record of recent, noteworthy publications; and
- whose ongoing work holds promise for continued substantive contributions to progress in the field of cancer.
Deadline: September 12
Case CCC Clinical Trials Funding Opportunity
The Case Comprehensive Cancer Center is announcing the availability of Protocol Specific Research Support (PSRS) funding for Year 2011. The budgeted funds are for the conduct of early phase clinical trial and restricted to support research nurses and data managers directly involved in the conduct of these clinical trials. Studies developed jointly between UH and CCF with planned accrual at both institutions will be prioritized. Please direct questions and requests for information about the funding process to Katarzyna Karelus, Administrative Director, Case Comprehensive Cancer Center Clinical Research Office, at (216) 368-6287 firstname.lastname@example.org.
Clinical and Translational Science Collaborative (CTSC) Pilot Grant Awards
Congratulations to the following Cancer Center members who were recently named recipients of CTSC Annual Pilot Grant Funding:
Nora Nock, PhD: Revving-Up Exercise for Sustained Weight-Loss by Altering Neurological Reward and Drive (REWARD): A Pilot Study of Assisted Exercise in Obese Endometrial Cancer Patients
GQ Zhang, PhD: FEMI: Federation of EMR and Medicaid Information for Healthcare Policy and Outcomes Research
Call for Applications: Merrill J. Egorin Workshop in Cancer Pharmacology
The Cancer Education Consortium is pleased to announce its annual workshop to be held September 23-26 in Leesburg, Virginia. This 3-day interactive workshop offers a broad-based curriculum that covers a range of topics related to new drug development and clinical evaluation. Expert speakers will lead discussions and present important didactic information regarding the preclinical and clinical evaluation of cytotoxic and targeted drugs, the identification and use of biomarkers, the special challenges of evaluating combination therapies, the problem of pharmacodynamic and pharmacokinetic drug interactions, and effects of organ dysfunction on drug disposition and toxicity. The discussion will include a focus on validation of targets and confirmation of mechanism of action and resistance in clinical trials. The 20-25 scholars selected will have ample opportunity for one-on-one interface with the nationally renowned faculty as well as peer-to-peer networking. Specialized evening workshops will also include sessions on new drugs, utility of biomarkers for selection of subjects and for prediction of response, and late breaking developments in cancer therapeutics.
Application Deadline: June 13
**All events are open to anyone interested in attending
Mitch Kronenberg, PhD
President and Chief Scientific Officer
La Jolla Institute for Allergy and Immunology
Topic: HVEM: A TNF Family Receptor Important for Regulating Innate Immunity and Inflammation in the Mucosa
12 pm Kulas Auditorium
Cancer Biology Invited Speaker Seminar
Donna Hansel, MD, PhD
Associate Professor, Anatomic Pathology
Topic: Bladder Cancer on the Move: mTOR and Migration
11 am NC1-202 Cleveland Clinic
Developmental Therapeutics Program meeting canceled
Hematology and Oncology Division Research Conference
Lisa Arfons, MD
Assistant Professor, Div. of Hem/Onc
Topic: Trends in Resident and Fellow Education: The Clinical Skills Block
8 am Lerner Tower B-151
Hematology/Oncology Fellows Seminar canceled
Taussig Cancer Institute Grand Rounds
Stephen Nimer, MD
Alfred P. Sloan Chair, Leukemia Service
Memorial Sloan-Kettering Cancer Center
Topic: Histone Modifying Enzymes: Defining Their Role in Hematologic Malignancies
8 am R3/002-003 Cleveland Clinic
Institute for Transformative Molecular Medicine Special Seminar
Reza Ardehali, MD, PhD
Div. of Cardiovascular Medicine
Institute for Stem Cell Biology and Regenerative Medicine
Topic: Prospective Identification of Cardiovascular Progenitors from Human Embryonic Stem Cells
10 am WRB 5136
Cancer Center Research in Progress Seminar
Kenneth R. Cooke, MD
Associate Professor, Pediatric Hem/Onc
Director, Bone Marrow Transplant
Topic: Translational Research Efforts to Improve Outcomes Following Allogeneic Stem Cell Transplantation
4 pm WRB 3-136
Case CCC Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
ASCO Review 2011
InterContinental Hotel and Bank of America Conference Center
Case CCC Annual Scientific Retreat
ADDITIONAL UPCOMING SEMINARS & EVENTS
International Society for Stem Cell Research (ISSCR) Annual Meeting
Cancer Health Disparities Summit 2011
Bethesda North Marriott Hotel in Rockville, Maryland
8th International Conference of the Society for Integrative Oncology: Innovating Integrative Oncology: New Science, New Solutions
InterContinental Hotel Cleveland